Telomir Pharmaceuticals (TELO) Competitors $4.27 +0.02 (+0.47%) Closing price 04:00 PM EasternExtended Trading$4.44 +0.18 (+4.10%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends TELO vs. XERS, PGEN, HUMA, TECX, TKNO, MLYS, SNDL, TRDA, KMDA, and RNACShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Xeris Biopharma (XERS), Precigen (PGEN), Humacyte (HUMA), Tectonic Therapeutic (TECX), Alpha Teknova (TKNO), Mineralys Therapeutics (MLYS), SNDL (SNDL), Entrada Therapeutics (TRDA), Kamada (KMDA), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Xeris Biopharma Precigen Humacyte Tectonic Therapeutic Alpha Teknova Mineralys Therapeutics SNDL Entrada Therapeutics Kamada Cartesian Therapeutics Xeris Biopharma (NASDAQ:XERS) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Which has stronger earnings and valuation, XERS or TELO? Telomir Pharmaceuticals has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$163.91M3.27-$62.26M-$0.45-8.00Telomir PharmaceuticalsN/AN/A-$13.07M-$0.58-7.36 Does the media refer more to XERS or TELO? In the previous week, Telomir Pharmaceuticals had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Telomir Pharmaceuticals and 0 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.00 beat Telomir Pharmaceuticals' score of -0.42 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Overall Sentiment Xeris Biopharma Neutral Telomir Pharmaceuticals Neutral Does the MarketBeat Community believe in XERS or TELO? Xeris Biopharma received 144 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformXeris BiopharmaOutperform Votes14469.90% Underperform Votes6230.10% Telomir PharmaceuticalsN/AN/A Do analysts recommend XERS or TELO? Xeris Biopharma presently has a consensus price target of $5.15, indicating a potential upside of 43.06%. Given Xeris Biopharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Xeris Biopharma is more favorable than Telomir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in XERS or TELO? 42.8% of Xeris Biopharma shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is XERS or TELO more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xeris Biopharma-33.69% N/A -17.38% Telomir Pharmaceuticals N/A -1,170.58%-832.67% SummaryXeris Biopharma beats Telomir Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.08M$6.93B$5.81B$9.18BDividend YieldN/A2.90%5.29%4.00%P/E Ratio-7.369.8526.0719.43Price / SalesN/A289.06460.2377.15Price / CashN/A75.4646.0938.87Price / Book213.505.577.415.07Net Income-$13.07M$123.72M$3.19B$222.90M7 Day Performance-5.53%-2.08%-0.23%0.37%1 Month Performance-5.11%1.11%6.21%5.51%1 Year Performance-39.09%5.75%26.11%23.18% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir PharmaceuticalsN/A$4.27+0.5%N/A-32.0%$127.08MN/A-7.361XERSXeris Biopharma3.2524 of 5 stars$3.57+0.6%$5.15+44.3%+21.4%$529.24M$187.36M-7.93290PGENPrecigen4.0238 of 5 stars$1.78+4.7%$7.00+293.3%+33.6%$521.31M$6.22M-3.24190HUMAHumacyte3.2093 of 5 stars$4.13-0.5%$13.71+232.1%+2.3%$519.80M$1.57M-3.08150Short Interest ↓TECXTectonic Therapeutic3.0221 of 5 stars$34.77-4.6%$80.50+131.5%N/A$512.86MN/A-5.90120Short Interest ↑Gap UpTKNOAlpha Teknova0.8169 of 5 stars$9.17+1.8%$8.50-7.3%+135.4%$488.85M$36.68M-12.39240Analyst ForecastPositive NewsGap UpMLYSMineralys Therapeutics3.0921 of 5 stars$9.51-3.1%$30.00+215.5%-27.8%$488.23MN/A-2.9128Earnings ReportAnalyst ForecastNews CoverageGap DownSNDLSNDL3.9889 of 5 stars$1.85-0.5%$3.25+75.7%+31.9%$486.14M$673.33M-5.972,516TRDAEntrada Therapeutics2.7396 of 5 stars$12.86-0.6%$25.67+99.6%-16.3%$481.22M$129.01M8.09110KMDAKamada4.4569 of 5 stars$8.33+8.3%$14.50+74.1%+34.6%$478.81M$142.52M29.75360Short Interest ↓News CoveragePositive NewsGap UpHigh Trading VolumeRNACCartesian Therapeutics2.5974 of 5 stars$18.51+0.8%$42.86+131.5%-9.9%$470.43M$47.94M-0.3564Analyst Revision Related Companies and Tools Related Companies Xeris Biopharma Alternatives Precigen Alternatives Humacyte Alternatives Tectonic Therapeutic Alternatives Alpha Teknova Alternatives Mineralys Therapeutics Alternatives SNDL Alternatives Entrada Therapeutics Alternatives Kamada Alternatives Cartesian Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TELO) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.